$MLTX insider trading
Over the last 12 months, MoonLake Immunotherapeutics insiders reported 1 buy totaling $99K and 19 sales totaling $129.6M across SEC Form 4 filings. 55% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $99K 1 event
- Sold · 12m
- $129.6M 19 events
- Events · 12m
- 20 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 55% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 1,100 | $20 | $22K | — | plan · indirect |
| Jul 22, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 52,448 | $20.02 | $1.0M | -1.9% | plan · 2 tranches · indirect |
| Jul 20, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 43,700 | $20.09 | $878K | -1.6% | plan · indirect |
| Jul 15, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 16,105 | $20.01 | $322K | -0.6% | plan · indirect |
| Jul 10, 2026 | Santos da Silva JorgeChief Executive Officer · O·D | ▼ Sale | 102,225 | $20.02 | $2.0M | -3.6% | plan · 2 tranches |
| Jul 1, 2026 | Santos da Silva JorgeChief Executive Officer · O·D | ▼ Sale | 47,775 | $20.03 | $957K | -1.6% | plan |
| Jun 22, 2026 | Bodenstedt MatthiasChief Financial Officer · O | ▼ Sale | 39,120 | $22.04 | $862K | -3.4% | plan |
| Jun 18, 2026 | Bodenstedt MatthiasChief Financial Officer · O | ▼ Sale | 17,876 | $19.67 | $352K | -1.5% | plan · 2 tranches |
| Jun 17, 2026 | Reich KristianChief Scientific Officer · O | ▼ Sale | 150,000 | $19.01 | $2.9M | -5% | plan · 3 tranches · indirect |
| Apr 14, 2026 | Bodenstedt MatthiasChief Financial Officer · O | ▼ Sale | 2,426 | $19.56 | $47K | -0.2% | plan |
| Apr 13, 2026 | Santos da Silva JorgeChief Executive Officer · O·D | ▼ Sale | 150,000 | $18.35 | $2.8M | -4.9% | 2 tranches |
| Apr 10, 2026 | Bodenstedt MatthiasChief Financial Officer · O | ▼ Sale | 87,795 | $18.95 | $1.7M | -6.9% | plan · 2 tranches |
| Mar 31, 2026 | BVF PARTNERS L P/ILD·10% | ▼ Sale | 3,750,000 | $16.79 | $63.0M | -78.3% | 3 tranches |
| Dec 19, 2025 | Bodenstedt MatthiasChief Financial Officer · O | ▽ Sale to issuer | 294,473 | — | — | -100% | — |
| Dec 19, 2025 | Reich KristianChief Scientific Officer · O | ▽ Sale to issuer | 35,389 | — | — | -100% | — |
| Dec 19, 2025 | Santos da Silva JorgeChief Executive Officer · O·D | ▽ Sale to issuer | 196,316 | — | — | -100% | — |
| Dec 9, 2025 | Santos da Silva JorgeChief Executive Officer · O·D | ▼ Sale | 200,000 | $14.87 | $3.0M | -6.5% | 2 tranches |
| Dec 9, 2025 | Reich KristianChief Scientific Officer · O | ▼ Sale | 202,908 | $14.85 | $3.0M | -100% | 2 tranches |
| Oct 8, 2025 | Bodenstedt MatthiasChief Financial Officer · O | ▲ Buy | 10,870 | $9.09 | $99K | +1.8% | — |
| Sep 30, 2025 | Chen Bihua | ▼ Sale | 6,499,978 | $7.21 | $46.9M | -76.5% | 5 tranches · indirect |
| Sep 2, 2025 | Reich KristianChief Scientific Officer · O | ▽ Sale to issuer | 48,978 | — | — | -58.1% | — |
Every $MLTX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? MoonLake Immunotherapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MLTX feed.